Cosibelimab (CK-301, TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. Featuring a functional Fc domain, this compound effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, including lymphoma cells [1].
CAS Number:
[2216751-26-5]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
